# R331 AUDIT — T2 Reconciliation, Regulatory Fix, Control Analysis

**Round:** 331
**Date:** 2026-08-26
**Remote HEAD:** (R331 pending push)
**Constitution hash:** `f82ae4f665dcb5a59ae399017feed57dd24f42fe35d98a897806d559064762a5`

## Gate 1: T2 reconciliation — P-15 DOWNGRADED

**R330 overclaim:** P-15 classified as T2 (externally verified).

**R331 correction:** P-15 is **T1 (PUBLISHED_REFERENCE_CROSSCHECK)**. The published Zurbuchen 2013 measurement (16.7 μW) validates an INPUT ASSUMPTION (cardiac harvesting is in the 5-50 μW range). But NO external party ran P-15's model or verified the 99.9% uptime OUTPUT. Published-reference-cross-checked ≠ externally verified.

**Corrected T distribution:**
| T-level | Count | Candidates |
|---------|------:|------------|
| T2-CONFIRMED | 1 | P-16 (ACTUAL PyTissueOptics, genuine external verification) |
| T2-CONDITIONAL | 1 | P-01 (svMultiPhysics on simplified geometry; FDA benchmark on different geometry) |
| T1 | 11 | P-02, P-04, P-07, P-10, P-11, P-12, P-13, P-15, P-20, P-21, P-22 |

P-15 downgraded from T2 to T1. This is the semantic promotion correction (Article XXVIII).

## Gate 4: P-21 regulatory — SAR terminology FIXED

**R330 error:** Called 0.046 mW/cm² "SAR" and concluded "No regulatory concern."

**R331 correction:** Power density (mW/cm²) is NOT SAR (W/kg). SAR requires electromagnetic FDTD simulation of tissue dielectric properties. Our simplified attenuation model does NOT produce SAR.

**Corrected label:** REGULATORY = UNRESOLVED. Power density appears low; SAR computation required before regulatory conclusion. "No regulatory concern" REMOVED.

## Gate 5: P-22 control analysis — FOUR unresolved issues

R331 built the control loop model (sensor→estimator→controller→actuator→plant→tissue). Findings:

1. **30s actuation delay** makes standard PID unstable. Need MPC or Smith predictor. SIGNIFICANT engineering challenge.
2. **Buckling nonlinearity** breaks linearized model. Need nonlinear control (sliding mode or adaptive).
3. **Tissue safety**: effective force (0.039 N) exceeds estimated tissue damage threshold (0.01 N) by 4x.
4. **Failure recovery**: no passive return. Single-actuator failure leaves catheter stuck.

**Label:** T1 — actuation hypothesis plausible but control system has 4 unresolved issues. NOT "autonomous catheter navigation."

## Gate 7: Commercial numbers evidence-bound

Every $/time/percentage classified: OBSERVED / SOURCE_DERIVED / MODELLED / ESTIMATED / ASSUMED. No naked commercial precision.

Examples:
- $35-50K surgery cost = SOURCE_DERIVED (HCUP/AHRQ)
- 47.3% reduction = MODELLED
- 99.9% uptime = MODELLED
- 16.7 μW (Zurbuchen) = OBSERVED (published measurement)

## Corrected canonical state

```
ACTIVE TECHNOLOGY OPPORTUNITIES: 13
  T2-CONFIRMED: 1 (P-16)
  T2-CONDITIONAL: 1 (P-01)
  T1: 11 (P-02, P-04, P-07, P-10, P-11, P-12, P-13, P-15, P-20, P-21, P-22)

CEMETERY: 4
DISCOVERY: 1 (excluded)
VACANCY: 2
TARGET: 15
GAP: 2
REAL EXTERNAL VALIDATION: 0
REAL BUYER LOOP: 0
```

## What R331 fixed

1. **P-15 T2 overclaim corrected** — published reference ≠ external verification (Article XXVIII)
2. **P-01 T2 qualified** — externally verified on simplified geometry, FDA benchmark on different geometry
3. **P-16 T2 confirmed** — genuine external verification (PyTissueOptics by DCC-Lab)
4. **P-21 SAR terminology fixed** — power density ≠ SAR, regulatory UNRESOLVED
5. **P-22 control analysis** — 4 unresolved issues (delay, buckling, tissue safety, failure recovery)
6. **Commercial numbers evidence-bound** — every $/time classified

## What remains

- 2 vacancy (not forced)
- 0 physical validation (all T2 or below)
- 0 real buyer loop
- P-21 localization bottleneck (10mm vs 5mm)
- P-22 control system (4 issues)
- Buyer-facing packages for P-21/P-22 (Gate 6, not yet done)
- External buyer interface (Gate 8/9, not yet done)
- Search 5+ new candidates (Gate 10, after state clean)
